Clinical Trial Search

Primary: Percentage of Participants With Combined Remission of Perianal Fistulising Crohn's Disease (CD) at Week 24 — 59.1 percentage of participants

Primary: Percentage of Participants With Combined Remission at Week 24 — 46.32; 48.76 percentage of participants — p==0.571

Primary: Meta-Scores of the 12-Item Short Form Health Survey (SF-12) Questionnaire's Physical Component Score [PCS-12] — 45.36 score on a scale

Primary: Objective 1: Number of CD Participants Who Have CPAF Using Various Codes in an TOH Database — 120; 120; 127; 127 Participants

Primary: The Total Number of Deregulated Genes at Week 4 — 0; 0 Deregulated genes

Primary: Percentage of Participants Who Achieved Combined Fistula Response at Week 24 — 47.1; 29.2; 25.0 percentage of participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 40; 43 Participants

Primary: Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline) — 75.0; 75.0 percentage…

Primary: Number of Participants With Durable Fistula Healing — 7; 8 participants

Primary: Fistula Healing in Patients at 6 Months Following Surgery — 56.7; 43.3 percentage of participants

Primary: Percentage of Participants With Mucosal Healing and No Deep Ulcerations — 30.3; 45.9 percentage of participants — p=0.010

Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate — 52.7; 60.1; 62.7; 47.7 Percentage of Participants — p=0.3393

Primary: Healing Success — 22; 25 participants — p=0.59

Primary: Percentage of Participants Achieving Endoscopic Remission at Week 26 — 34.5 percentage of participants

Primary: The Crohn's Disease Activity Index (CDAI)-70 Response Rate at Week 8 in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg — 30.6; 35.0; 49.3…

Primary: Number of Participants in Clinical Remission at Treatment Week 20. Clinical Remission Defined as Harvey Bradshaw Index (HBI) Score Less Than 5. — 492 Participants

Primary: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 — 144; 36 Participants — p=<0.0001

Primary: Remission After 8-week of Treatment — 17; 14 Participants — p=0.526

Primary: Percentage of Participants With Clinical Remission at Week 52 — 61.0; 64.9 percentage of participants

Primary: Induction Study: Percentage of Participants Who Achieved Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 10 — 32.9; 25.7; 19.8; 26.7 percentage of…

Primary: Number of Participants With Anal HPV of Any Type, Single Type, and Multiple Types — 41; 16; 25 participants

Primary: Percentage of Participants With Remission at Week 8 — 13.3; 23.1; 14.3; 19.5 percentage of participants — p=0.76

Primary: Percentage of Participants Who Achieve Endoscopic Remission at Week 12/16 — 0; 10.3; 8.1; 8.3 percentage of participants — p=0.056

Primary: Change in Disease Activity by Harvey Bradshaw Index — -5; -3 score on a scale

Primary: The Number and Percentage of Patients Achieving Clinical Response According to Crohn's Disease Activity Index (CDAI)-70 Criteria at Week 6 — 77; 81 Participants

Primary: Number of Participants With Serious Infections — 132; 47; 18 Participants

Primary: Number of Participants With Clinical Response at Week 6 — 31; 48; 45; 52 Participants — p=0.005

Primary: Proportion of Patients With Endoscopic Remission — 3; 3 Participants

Primary: The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease — 1 participants

Primary: Number of Participants With Clinical Response at Week 6 — 53; 84; 84 participants — p=0.002